Picolinic acid- or desferrioxamine-inducible autocrine activation of macrophages engineered to produced IFNγ: An approach for gene therapy

Gene Therapy

Volumn 11, Issue 6, 2004, Pages 560-568

  Pastorino, S ^a,c,d   Carta, L ^a,d   Puppo, M ^a   Melillo, G ^b   Bosco, M C ^a   Varesio, L ^a  

^a G GASLINI INSTITUTE   (Italy)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Desferrioxamine; Interferon ; Macrophages; Picolinic acid; Shuttle vectors

Indexed keywords

DEFEROXAMINE; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERFERON REGULATORY FACTOR 1; IRON CHELATING AGENT; NITRIC OXIDE; PICOLINIC ACID; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; AUTOCRINE EFFECT; CELL BASED GENE THERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; EXTRACELLULAR SPACE; GENE EXPRESSION; GENE INDUCTION; GENETIC ENGINEERING; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOSTIMULATION; IRON CHELATION; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PHAGOCYTOSIS; PRIORITY JOURNAL; PROMOTER REGION; SHUTTLE VECTOR;

ANIMALS; AUTOCRINE COMMUNICATION; CELL LINE; DEFEROXAMINE; DRUG SYNERGISM; GENE THERAPY; GENETIC VECTORS; INTERFERON TYPE II; IRON; IRON CHELATING AGENTS; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED C57BL; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PHAGOCYTOSIS; PICOLINIC ACIDS; STIMULATION, CHEMICAL; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

MURINAE; VECTORS;

EID: 1842477403     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302217     Document Type: Article

References (34)

1. Varesio L et al. Role of cytokines in the activation of monocytes. In: Aggarwal BB, Puri RK (ed) Human Cytokines: Their Role in Disease and Therapy. Blackwell Scientific Publication: Cambridge, 1995, pp 55-70.
2. Ahuja SS, Mummidi S, Malech HL, Ahuja SK. Human dendritic cell (DC)-based anti-infective therapy: Engineering DCs to secrete functional IFNγ and IL-12. J Immunol 1998; 161: 868-876.
3. Melero I, Vile RG, Colombo MP. Feeding dendritic cells with tumor antigens: Self-service buffet or a la carte? Gene Therapy 2000; 7: 1167-1170.
4. Pastorino S et al. Generation of high-titer retroviral vector-producing macrophages as vehicles for in vivo gene transfer. Gene Therapy 2001; 8: 431-441.
5. Gough PJ, Raines EW. Gene therapy of apolipoprotein E-deficient mice using a novel macrophage-specific retroviral vector. Blood 2003; 101: 485-491.
6. Ringenbach L et al. Polyethylenimine-mediated transfection of human monocytes with the IFNγ gene: An approach for cancer adoptive immunotherapy. Gene Therapy 1998; 5: 1508-1516.
7. Lei H et al. Induction of potent antitumor response by vaccination with tumor lysate-pulsed macrophages engineered to secrete macrophages colony-stimulating factor and interferon-γ. Gene Therapy 2000; 7: 707-713.
8. Wu M et al. Genetically engineered macrophages expressing IFN-gamma restore alveolar immune function in SCID mice. Proc Natl Acad Sci USA 2001; 98: 14589-14594.
9. Melillo G et al. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Exp Med 1995; 182: 1683-1693.
10. Lewis JS et al. Macrophage responses to hypoxia: Relevance to disease mechanisms. J Leukocyte Biol 1999; 66: 889-900.
11. Carta L et al. Engineering of macrophages to produce IFN-gamma in response to hypoxia. J Immunol 2001; 166: 5374-5380.
12. Griffiths L et al. The macrophage - a novel system to deliver gene therapy to pathological hypoxia. Gene Therapy 2000; 7: 255-262.
13. Semenza GL. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 2000; 35: 71-103.
14. Melillo G et al. Regulation of inducible nitric oxide synthase expression in IFN-gamma-treated murine macrophages cultured under hypoxic conditions. J Immunol 1996; 157: 2638-2644.
15. Melillo G et al. Functional requirement of the hypoxia-responsive element in the activation of the inducible nitric oxide synthase promoter by the iron chelator desferrioxamine. J Biol Chem 1997; 272: 12236-12243.
16. Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood 1993; 82: 3610-3615.
17. Varesio L et al. Picolinic acid, a catabolite of tryptophan, as the second signal in the activation of IFN-gamma-primed macrophages. J Immunol 1990; 145: 4265-4271.
18. Melillo G et al. Regulation of nitric oxide synthase mRNA expression by interferon-gamma and picolinic acid. J Biol Chem 1994; 269: 8128-8133.
19. Gendelman HE, Morahan PS. Macrophages in Viral Infections. IRL Press: Oxford, 1994: 157-213.
20. Stark GR et al. How cells respond to interferons. Annu Rev Biochem 1998; 67: 227-264.
21. 1 arrest induced by picolinic acid. Biochem Biophys Res Commun 1977; 78: 136.
22. Bosco MC et al. The tryptophan catabolite picolinic acid selectively induces the chemokines macrophage inflammatory protein-1α and -1β in macrophages. J Immunol 2000; 164: 3283-3291.
23. Dachs GU et al. Targeting gene expression to hypoxic tumor cells. Nat Med 1997; 3: 515-520.
24. Ido A et al. Selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human α-fetoprotein promoter. Cancer Res 2001; 61: 3016-3021.
25. Shibata T, Giaccia AJ, Brown JM. Development of a hypoxia-responsive vector for tumor-specific gene therapy. Gene Therapy 2000; 7: 493-498.
26. Modlich U, Pugh CW, Bicknell R. Increasing endothelial cell specific expression by the use of heterologous hypoxic and cytokine-inducible enhancers. Gene Therapy 2000; 7: 896-902.
27. Richard DE, Berra E, Pouysségur J. Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1α in vascular smooth muscle cells. J Biol Chem 2000; 275: 26765-26771.
28. Pais TF, Appelgerg R. Macrophage control of mycobacterial growth induced by picolinic acid is dependent on host cell apoptosis. J Immunol 2000; 164: 387-389.
29. Krieger I. Picolinic acid in the treatment of disorders requiring zinc supplementation. Nutr Rev 1980; 38: 148-150.
30. Dazzi C et al. New high-performance liquid chromatographic method for the detection of picolinic acid in biological fluids. J Chromatogr B 2001; 751: 61-68.
31. Cox GW et al. Heterogeneity of hematopoietic cells immortalized by v-myc/v-raf recombinant retrovirus infection of bone marrow or fetal liver. J Natl Cancer Inst 1989; 81: 1492-1496.
32. 1 phase of the cell cycle. Cancer Res 1993; 53: 3968-3975.
33. Burke B et al. Expression of HIF-1alpha by human macrophages: implications for the use of macrophages in hypoxia-regulated cancer gene therapy. J Pathol 2002; 196: 204-212.
34. Abonour R et al. Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. Nat Med 2000; 6: 652-658.